Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2015

Open Access 01-12-2015 | Meeting abstract

Glycated hemoglobin follow-up of sis-hiperdia (Muriaé-Minas Gerais, Brazil)

Authors: Cláudio César Gusman Matias de Oliveira, Cláudio Rogério Matias de Oliveira, Gustavo Gusman Matias de Oliveira, Bruno Almeida Rocha Maciel, Matheus Sarabion Vilela Pereira, Vilma Aparecida Ferraz

Published in: Diabetology & Metabolic Syndrome | Special Issue 1/2015

Login to get access

Excerpt

The glycated hemoglobin (HbA1C) test, essential for diabetic patients follow-up, measures the concentrations of glycated hemoglobin in the blood, which can indicate, as they increase in proportion to glucose rates, the possibility of complications of the disease. Furthermore, the test points to the risk of Type 2 diabetes mellitus (T2D) development, for concentration values between 5.7% and 6.4%, and confirms its diagnosis if values exceed 6.5% in two different tests. In T2D patients, values above 7% imply heightened risk of microvascular complications and neuropathy. Several factors in the patients' lifestyle affect these values, such as the practice of physical activities, diet and weight control. …
Metadata
Title
Glycated hemoglobin follow-up of sis-hiperdia (Muriaé-Minas Gerais, Brazil)
Authors
Cláudio César Gusman Matias de Oliveira
Cláudio Rogério Matias de Oliveira
Gustavo Gusman Matias de Oliveira
Bruno Almeida Rocha Maciel
Matheus Sarabion Vilela Pereira
Vilma Aparecida Ferraz
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue Special Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-7-S1-A47

Other articles of this Special Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine